• Woodward EN, Flynn AWP, Mereish EH, Banks RJ, Marks AK, Pantalone DW. "I've Been Forged in Fire": Preliminary Theory of HIV Prevention Resilience Among Sexual Minority Men With HIV Risk Factors. AIDS Education and Prevention : Official Publication of The International Society For AIDS Education. 2025 Feb 1; 37(1):56-73.
• McGinnis KA, Justice AC, Marconi VC, Rodriguez-Barradas MC, Hauser RG, Oursler KK, Brown ST, Bryant KJ, Tate JP. Corrigendum: Combining Charlson comorbidity and VACS indices improves prognostic accuracy for all-cause mortality for patients with and without HIV in the Veterans Health Administration. Frontiers in medicine. 2025 Jan 8; 11:1532350.
• Lee KL, Sarovar V, Lam JO, Leyden WA, Alexeeff SE, Lea AN, Hechter RC, Hu H, Marcus JL, Yuan Q, Kramer JR, Lin LL, Chiao EY, Towner WJ, Horberg MA, Silverberg MJ. Excess Mortality in Persons with Concurrent HIV and Cancer Diagnoses: A Retrospective Cohort Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2024 Dec 2; 33(12):1698-1705.
• Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O, PURPOSE 2 Study Team. Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. The New England journal of medicine. 2024 Nov 27.
• Yu X, Kuo YF, Dike AA, Efejuku T, Raji MA, Berenson AB, Giordano TP. Trends and disparities in antiretroviral therapy prescription rates among US Medicare beneficiaries with HIV. HIV Medicine. 2024 Nov 25.

» View more Citations

• VA Successfully Implements Interferon-free Treatment for Hepatitis C Virus in Previously Undertreated Patient Populations
  This study examined the adoption of interferon-free treatment for hepatitis C virus (HCV) in VA to learn who received this therapy and whether the limitations of interferon-containing treatments have been overcome, including low rates of use among VA healthcare users who are African American or Hispanic, and among those with HCV-HIV co-infection. Findings showed that with the advent of interferon-...
  
  Date: March 7, 2018
• Evidence Review Identifies Modest Mortality Disparities among Racial and Ethnic Minority Groups in VA Healthcare
  To support VA’s efforts to better understand the scale and determinants of disparities in racial and ethnic mortality – and to develop interventions to reduce disparities, investigators from the VA Evidence-based Synthesis Program (ESP) Coordinating Center in Portland, OR conducted an evidence review of mortality disparities specific to VA. Findings showed that although VA’s equal access healthcar...
  
  Date: March 1, 2018
• Racial Disparities in HIV Quality of Care that May Extend to Common Comorbid Conditions
  To more fully understand patterns of racial disparities in the quality of care for persons with HIV infection, this study examined a national cohort of Veterans in care for HIV in the VA healthcare system during 2013. Findings showed that racial disparities were identified in quality of care specific to HIV infection – and in the care of common comorbid conditions. Blacks were less likely than whi...
  
  Date: September 22, 2016
• New Guidelines May Significantly Decrease Cost for Testing Immune Function in Veterans with HIV
  In 2012, the Department of Health and Human Services recommended CD4 testing in patients with HIV every 3 to 6 months – except in patients with consistently suppressed virus and sustained CD4 cell count, who could be tested every 6 to 12 months. In 2014, updated guidelines recommended that in individuals with viral suppression, CD4 testing be considered either optional or annual, depending on the ...
  
  Date: July 1, 2016
• Consequences of Notifying VA Patients about Potential Exposure to Large-Scale Adverse Events
  This study sought to determine the intended and unintended consequences of patient notification following a large-scale adverse event (LSAE) within the VA healthcare system, which systematically looks for LSAEs, tracks potentially exposed patients, and communicates with them after LSAE notification. Findings showed that more than two-thirds of potentially exposed patients returned for HCV, HBV, an...
  
  Date: May 1, 2015

» View more Publication Briefs

» View more Studies

QUERI Quarterly, June 2005, Vol 7, No 2 (06-23-2005)

QUERI Quarterly, June 2003 (06-24-2003)

» View more Cyberseminars

Videos

There are currently no videos for this topic.

Podcasts

There are currently no podcasts for this topic.

Other Resources

• Visit the HIV/AIDs information section of the VA's Office of Public Health website.
• Visit the Centers for Disease Control & Prevention HIV information section.
• Learn more about all VA research related to HIV on the VA Office of Research & Development’s infectious disease topic page.